• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·ALVMG.PA
Share

Visiomed Group S.A. Stocks

€ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

€ 61.32M

€ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally. It provides thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, and connected electrocardiograms; and pain relief products, such as electrotherapy. The company also offers connected scales and scalable baby scales, as well as prevention and treatment products, such as humidifiers and phototherapies. In addition, it provides hearing products and optics, including presbycusis, as well as family hygiene products. The company offers its products under the ThermoFlash, T. LeClerc, Visiocheck, Innoxa, and BewellConnect brands. Visiomed Group SA was founded in 2007 and is headquartered in Paris, France.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.06.2026 08:00

New AI, hardware for neural networks, quantum chip: what Microsoft showed to developers

03.06.2026 07:00

Trump signed a softened executive order on government vetting of new AI models before release

03.06.2026 01:12

Virgin Galactic is having its worst 1d performance ever, following 204% 7d rally

03.06.2026 00:20

Investors began to see HPE stock as a bet on AI: report lifted the securities by 37%

02.06.2026 23:13

Victoria's Secret stock soars 45% on beat earnings estimates and boosted outlook

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026